B7-33: The Single-Chain Relaxin Analogue for Fibrosis Research
24th Jul 2026
The study of fibrotic pathways remains a primary focus in extracellular matrix (ECM) research. B7-33, a novel single-chain peptide analogue of human gene-2 (H2) relaxin, represents a significant development in biochemical tools designed to investigate tissue remodelling. Unlike native H2 relaxin, which is a complex two-chain peptide, B7-33 is synthesised as a simplified single-chain variant. This structural modification preserves the high-affinity binding to the Relaxin Family Peptide Receptor 1 (RXFP1)—a class A G-protein-coupled receptor—while exhibiting a distinct signalling bias. In-vitro models demonstrate that B7-33 selectively activates the extracellular signal-regulated kinase (pERK1/2) pathway to promote collagen clearance, without significantly stimulating the cyclic adenosine monophosphate (cAMP) pathway that is often linked to unwanted proliferative responses. This analytical review examines the structural properties, receptor interaction dynamics, and laboratory applications of B7-33 within modern cellular research. When sourcing high-purity research reagents, selecting a reputable UK peptide supplier ensures experimental consistency and chemical integrity.
Structural Architecture and Receptor Bias
Native H2 relaxin consists of an A-chain and a B-chain linked by disulfide bonds, making its chemical synthesis highly complex and costly. Researchers sought to synthesise a functional single-chain analogue to facilitate more efficient laboratory investigations. B7-33 was engineered by truncating the B-chain of H2 relaxin (specifically residues 1-27) and solubilising it without the A-chain. This structural refinement allows the peptide to maintain its active conformation required for RXFP1 interaction, specifically targeting the extracellular leucine-rich repeat domain.
When analysing receptor dynamics in cellular models, B7-33 displays a unique signalling bias. In cells expressing RXFP1, such as primary fibroblasts, the peptide binds to the receptor and preferentially triggers the phosphorylation of ERK1/2. Crucially, B7-33 does not stimulate significant cAMP accumulation in most cell types, which differentiates its functional profile from native relaxin. This pathway selectivity is highly valued in laboratory research, as it allows investigators to isolate the anti-fibrotic mechanisms of RXFP1 activation from other systemic intracellular cascades. Researchers can acquire high-purity reagents to explore these pathways by visiting the shop all peptides section of our platform.
In-Vitro Applications in Extracellular Matrix Regulation
In-vitro experiments using B7-33 focus heavily on its capacity to modulate the synthesis and degradation of ECM components. When applied to cultured fibroblasts stimulated with transforming growth factor-beta 1 (TGF-beta 1), B7-33 exhibits robust regulatory properties:
To understand the utility of B7-33, it is helpful to contrast its properties with native H2 relaxin:
In-Vitro Research FAQs
What is the primary molecular pathway activated by B7-33 in cell culture?
B7-33 primarily activates the pERK (phosphorylated extracellular signal-regulated kinase) pathway via the RXFP1 receptor. Unlike native H2 relaxin, it does not trigger significant cyclic adenosine monophosphate (cAMP) accumulation, allowing researchers to study isolated anti-fibrotic signalling.
How does the single-chain structure of B7-33 affect its stability in laboratory assays?
The single-chain structure of B7-33, lacking the complex disulfide linkages of native relaxin, simplifies synthesis and enhances stability in specific experimental environments. However, like all peptides, it remains susceptible to enzymatic degradation in serum-containing media, requiring careful experimental design.
What reconstitution solvent is recommended for preparing B7-33 for in-vitro assays?
For laboratory research, B7-33 should be reconstituted using a sterile reconstitution solvent or sterile phosphate-buffered saline (PBS). For long-term storage or to prevent microbial growth in multi-use vials, a specialised bacteriostatic reconstitution solution may be employed.
Structural Architecture and Receptor Bias
Native H2 relaxin consists of an A-chain and a B-chain linked by disulfide bonds, making its chemical synthesis highly complex and costly. Researchers sought to synthesise a functional single-chain analogue to facilitate more efficient laboratory investigations. B7-33 was engineered by truncating the B-chain of H2 relaxin (specifically residues 1-27) and solubilising it without the A-chain. This structural refinement allows the peptide to maintain its active conformation required for RXFP1 interaction, specifically targeting the extracellular leucine-rich repeat domain.
When analysing receptor dynamics in cellular models, B7-33 displays a unique signalling bias. In cells expressing RXFP1, such as primary fibroblasts, the peptide binds to the receptor and preferentially triggers the phosphorylation of ERK1/2. Crucially, B7-33 does not stimulate significant cAMP accumulation in most cell types, which differentiates its functional profile from native relaxin. This pathway selectivity is highly valued in laboratory research, as it allows investigators to isolate the anti-fibrotic mechanisms of RXFP1 activation from other systemic intracellular cascades. Researchers can acquire high-purity reagents to explore these pathways by visiting the shop all peptides section of our platform.
In-Vitro Applications in Extracellular Matrix Regulation
In-vitro experiments using B7-33 focus heavily on its capacity to modulate the synthesis and degradation of ECM components. When applied to cultured fibroblasts stimulated with transforming growth factor-beta 1 (TGF-beta 1), B7-33 exhibits robust regulatory properties:
- Inhibition of Myofibroblast Differentiation: B7-33 exposure limits the expression of alpha-smooth muscle actin (alpha-SMA), a key marker of myofibroblast transformation.
- Reduction of Collagen Synthesis: The peptide significantly decreases the transcription and secretion of Collagen Type I and Type III in active fibroblast cultures.
- Upregulation of Matrix Metalloproteinases: B7-33 increases the activity of MMP-2 and MMP-9, enzymes responsible for degrading excess collagen matrices.
- Suppression of TIMPs: It downregulates tissue inhibitors of metalloproteinases, thereby facilitating an environment conducive to matrix degradation.
Laboratory Insight: When preparing B7-33 for cellular assays, researchers must exercise caution during reconstitution. The peptide should be dissolved in a sterile reconstitution solvent to maintain structural integrity. Avoid vigorous mechanical agitation, such as vortexing, which can lead to peptide shear or aggregation. Instead, gentle swirling is recommended to ensure complete dissolution before introducing the reagent to culture media.
Comparative Analysis: Native Relaxin-2 vs B7-33To understand the utility of B7-33, it is helpful to contrast its properties with native H2 relaxin:
- Chain Structure: Native H2 relaxin is a dual-chain peptide with three disulfide bonds; B7-33 is a single-chain peptide lacking complex inter-chain disulfide bridges.
- Synthesis Complexity: Native relaxin requires difficult multi-step synthesis; B7-33 is highly amenable to standard solid-phase peptide synthesis, reducing production overheads.
- Signalling Profile: Native relaxin activates both cAMP and pERK pathways; B7-33 selectively activates the pERK pathway.
- Receptor Affinity: Both show high affinity for the RXFP1 receptor, but B7-33 exhibits minimal cross-reactivity with other relaxin-family receptors.
In-Vitro Research FAQs
What is the primary molecular pathway activated by B7-33 in cell culture?
B7-33 primarily activates the pERK (phosphorylated extracellular signal-regulated kinase) pathway via the RXFP1 receptor. Unlike native H2 relaxin, it does not trigger significant cyclic adenosine monophosphate (cAMP) accumulation, allowing researchers to study isolated anti-fibrotic signalling.
How does the single-chain structure of B7-33 affect its stability in laboratory assays?
The single-chain structure of B7-33, lacking the complex disulfide linkages of native relaxin, simplifies synthesis and enhances stability in specific experimental environments. However, like all peptides, it remains susceptible to enzymatic degradation in serum-containing media, requiring careful experimental design.
What reconstitution solvent is recommended for preparing B7-33 for in-vitro assays?
For laboratory research, B7-33 should be reconstituted using a sterile reconstitution solvent or sterile phosphate-buffered saline (PBS). For long-term storage or to prevent microbial growth in multi-use vials, a specialised bacteriostatic reconstitution solution may be employed.
- Hossain, M. A., et al. (2016). 'A single-chain peptide agonist of the relaxin receptor RXFP1.' Chemical Science, 7(6), 3805-3819. View published research
- Bathgate, R. A., et al. (2013). 'Relaxin family peptides and their receptors.' Physiological Reviews, 93(1), 405-480. View published research
- Chow, B. S., et al. (2019). 'The relaxin receptor RXFP1 signalling pathways.' Frontiers in Physiology, 10, 605. View published research
- Samuel, C. S., et al. (2017). 'Anti-fibrotic actions of relaxin-2 and its single-chain analogue B7-33.' British Journal of Pharmacology, 174(10), 1012-1021. View published research
- Wang, C., et al. (2020). 'In-vitro evaluation of B7-33 on extracellular matrix deposition in cardiac fibroblasts.' Journal of Molecular and Cellular Cardiology, 142, 55-64. View published research
⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.